CN1424083A - Medicine for thrombotic diseases - Google Patents
Medicine for thrombotic diseases Download PDFInfo
- Publication number
- CN1424083A CN1424083A CN02151507A CN02151507A CN1424083A CN 1424083 A CN1424083 A CN 1424083A CN 02151507 A CN02151507 A CN 02151507A CN 02151507 A CN02151507 A CN 02151507A CN 1424083 A CN1424083 A CN 1424083A
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- scolopendra
- pheretima
- scorpio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating the thrombotic disease of peripheral blood vessel is prepared from 5 Chinese-medicinal materials including astragalus root, earthworm, ground beetle, etc. Its advantages are sure curative effect and no toxic by-effect.
Description
(1) technical field
The invention belongs to a kind of medicine for the treatment of the peripheral vessels thrombotic disease, particularly a kind of medicine with treatment by Chinese herbs peripheral vessels thrombotic disease.
(2) background technology
The peripheral vessels thrombotic disease comprises peripheral arterial occlusion disease and venous thromboembolism disease.At present, the Epidemiological study data shows, peripheral vascular disease has become common disease at present, with occlusive atherosclerosis (ASO) is example, present old people greater than 60 years old has 100,000,000 3 thousand ten thousand, estimate that ASO patient has 2,000 ten thousand, and increasing progressively that person ASO sickness rate is 2,50/,100,000 people more than 45 years old with about 600,000 people's of year speed.And, the disability rate height of peripheral vessels thrombotic disease, or leave over the intractable sequela.But, also there is not specific medicine effectively to treat at present, bring very big misery to patient.
(3) summary of the invention
The object of the present invention is to provide a kind of easy to usely, curative effect is reliable, the medicine of the treatment peripheral vessels thrombotic disease that has no side effect.
The object of the present invention is achieved like this:
The invention discloses a kind of medicine for the treatment of the peripheral vessels thrombotic disease, is the medicament of being made by the following weight proportion raw material
Radix Astragali 200-400 Pheretima 200-400 Eupolyphaga Seu Steleophaga 200-400
Scolopendra 50-150 Scorpio 50-150
More preferably proportioning is:
Radix Astragali 300-400 Pheretima 300-400 Eupolyphaga Seu Steleophaga 300-400
Scolopendra 80-120 Scorpio 80-120
Medicine of the present invention in order to increase therapeutic effect, discloses the another kind of medicament of being made by the following weight proportion raw material
Radix Astragali 200-400 Pheretima 200-400 Eupolyphaga Seu Steleophaga 200-400
Scolopendra 50-150 Scorpio 50-150
Radix Salviae Miltiorrhizae 100-300 Radix Angelicae Sinensis 100-300 Radix Cyathulae 100-300
More preferably weight proportion is:
Radix Astragali 300-400 Pheretima 300-400 Eupolyphaga Seu Steleophaga 300-400
Scolopendra 80-120 Scorpio 80-120
Radix Salviae Miltiorrhizae 120-240 Radix Angelicae Sinensis 120-240 Radix Cyathulae 120-240
Preferred weight proportion is:
Radix Astragali 320-380 Pheretima 320-360 Eupolyphaga Seu Steleophaga 320-370
Scolopendra 90-120 Scorpio 90-120
Radix Salviae Miltiorrhizae 150-200 Radix Angelicae Sinensis 150-200 Radix Cyathulae 150-200
Most preferred weight proportion is;
The Radix Astragali 380 Pheretimas 360 Eupolyphaga Seu Steleophagas 320
Scolopendra 120 Scorpios 120
Radix Salviae Miltiorrhizae 170 Radix Angelicae Sinensis 170 Radix Cyathulaes 170
Medicine of the present invention can situation be made capsule, pill or other form of Chinese drug.The foundation and the general thought of the main component of 1 each component of medicine of the present invention and production technology 1.1 technological designs:
The design of this extraction process is according to the prescription contained effective ingredient of 8 herbal medicines and the physicochemical property of main component and the specific requirement of capsule formulation, with reference to extracting method and the traditional medication custom of same medicine in other Chinese patent medicine preparation, 8 herbal medicines of will writing out a prescription are divided into that decocting boils, three parts directly are used as medicine after ethanol extraction and the pulverizing.1.2 determining of water boiling and extraction medicine:
The Radix Astragali in the prescription mainly contains multiple water soluble ingredients such as first glycosides, astragalus polysaccharides, is the main effective ingredient of the Radix Astragali with 2 kinds of main water soluble ingredients in the Radix Astragali.Pheretima, Eupolyphaga Seu Steleophaga 2 herbal medicines are animal drugs, Pheretima mainly contains lumbrifebrine (lumbrofebrine), lumbricin (lumbritin), terrestro-lumbrolysin (lumbrolgsin), thrombosis lysotoxin and leucine, several amino acids such as glutamic acid, external antithrombotic test shows, 1: 1 Pheretima water liquid has tangible thrombus dissolving effect and tangible fibrinolytic, the test of animal antithrombotic shows that the Pheretima aqueous extract has the thrombotic effect that obviously presses down, Eupolyphaga Seu Steleophaga mainly contains protein soluble in water, polypeptide, compositions such as several amino acids, pharmacological testing shows that its decocting liquid has tangible anti thrombotic action, mainly contain the character of water solublity effective ingredient according to above three herbal medicines, so adopt the decocting cooking method to extract the effective ingredient of medicine to the three.And amount of water, decocting time, the decoction number of times that influences extraction efficiency carried out the orthogonal optimum seeking test of three factors, three levels, and determine to add the water of 10 times of amounts, decocts 2 times, each 2h boils condition for the decocting that suits.1.3 determining of alcohol extraction medicine:
Radix Salviae Miltiorrhizae in the prescription both contained antibacterial and anti-inflammation functions in the liposoluble constituent of TANSHINONES series such as TANSHINONES HA, cryptotanshinone, contain blood circulation promoting and blood stasis dispelling again, multiple water soluble ingredients such as microcirculation improvement and hemorheological danshensu, former a little tea aldehyde and salviol, tanshinol.Contain multiple volatile ingredient and multiple water soluble ingredients such as ferulic acid, terpene alcohol, folic acid, butanoic acid, uracil and adenine such as Artemisia benzene lactone (liguslilide) in the Radix Angelicae Sinensis.Mainly contain phytosterin compounds such as cherishing Herba Amaranthi tricoloris sterol, different bosom Herba Amaranthi tricoloris sterone, amarasterone A, B and ecdyson etc. in the Radix Cyathulae, these compositions all are soluble in the ethanol.Character according to the contained main component of above three flavor medicines, so in extraction process, adopt the alcohol heating reflux extraction that two constituents is all had good solubility, and concentration of alcohol, alcohol adding amount and the extraction time (being the time) that influences alcohol extraction efficient carried out the optimization test of three factors, three levels, determine to adopt 75% ethanol, add 8 times of amounts, reflux, extract, 3 times (2,1.5,1.5h) be the optimum of alcohol extraction.Add determining of medicine 1.4 directly pulverize:
To the Scolopendra in the prescription, the more valuable animal drugs of Scorpio 2 flavors, according to traditional medication custom and this product is the characteristics of capsule, so after 2 flavor oven dry pulverizing, replace adjuvant directly to add and extract in the extractum, make extraction extractum be easy to oven dry, pulverize, and can alleviate the moisture absorption of medicine, both fully kept the effective ingredient of 2 herbal medicines, save adjuvant again, reduced cost.1.5 moulding process and dosage form:
More than determining on the basis of each extract drugs technology, moulding process to the capsule preparation is studied, merge by extracting herbal decoction and ethanol extraction cream, with Scolopendra, make the scorpion fine powder and replace adjuvant to add after, oven dry, pulverize and incapsulate, result of the test shows that its total dried cream powder must be measured with dose and all suit.
Certainly, medicine of the present invention also can make ball shape or other form of Chinese drug.2. medicine effect of the present invention is learned experimentation 2.1 rat limb ischemia partial side Zhi Xunhuan and hemorheological result of the tests
1. medicine of the present invention can improve the ordinary circumstance of femoral artery ligation rat model, be that body weight gain speed is faster than the model control group rat, the recovery of suffering from limb skin temperature and color all is better than model control group, illustrates that medicine of the present invention can quicken femoral artery ligation rat model ischemia side and prop up circulation formation; 2. medicine of the present invention to the rising of femoral artery ligation rat model hemorheological property and platelet aggregation in certain inhibitory action or improvement trend; 3. angiography and tissue slice result show, can set up side Zhi Xunhuan with medicine of the present invention, and increase with dosage, and it is big more that the side that is formed by internal iliac artery is propped up the systemic vascular area.Heavy dose of group is 0.693 ± 0.026 (P＜0.01), middle dosage group is 0.533 ± 0.239 (P＜0.01), small dose group is 0.354 ± 0.237 (P＞0.05), tremulous pulse clearing end to ankle joint length increases with dosage in the ligation side shin, distance also shortens more, the heavy dose of group of medicine of the present invention is 1.04 ± 0.46 (P＜0.01), middle dosage level is 1.025 ± 0.27 (P＜0.01), small dose group is 2.16 ± 0.79 (P＞0.05), and medicine of the present invention really improves significantly to rat limb ischemia partial side Zhi Xunhuan.
Can find out by lower limb tissue slice image analysis vessel density is reduced, increase with vessel density behind the medicine of the present invention, it is 102.37 ± 45.38 (P＜0.01) for heavy dose of group that the ligation limb subtracts strong limb difference, and middle dosage group is that 90.66 ± 39.34 (P＜0.05) small dose group is 58.66 ± 58.79 (P＜0.05); The heavy dose of group of muscle fiber number and blood vessel ratio is-3.155 ± 3.642 (P＜0.01), and middle dosage group is-1.397 ± 3.317 (P＜0.05), and small dose group is-0.807 ± 2.238 (P＜0.01); The heavy dose of group of the muscle fiber area of each blood vessel domination is 65.00 ± 22.21 (P＜0.01), middle dosage group is 92.00 ± 30.77 (P＜0.01), small dose group is 40.00 ± 15.65 (P＜0.05), illustrate that medicine of the present invention forms side Zhi Xunhuan, increase vessel density, improve the circulation ischemic state, for clinical treatment has been established pharmacological basis.2.2 medicine of the present invention fills up the microcirculatory result of the test that influences to the rat foot:
The medicine of the present invention of range of doses can obviously suppress the inductive rat serum flow of high molecular dextran institute to be reduced, thereby microcirculation is improved.2.3 anti-inflammatory and antalgic result of the test:
The medicine of the present invention of doses has definite antiinflammatory, analgesic activity to animal.Medicine promptly 1. of the present invention can obviously suppress the hypertrophy of chronic granulation, and the antagonism angle rat paw edema that glue causes of picking up food with chopsticks improves the mice auricle swelling that dimethylbenzene causes.The antiphlogistic effects that it is shown is suitable with TONGSAIMAI PIAN 0.7g/kg, proves its antiinflammatory action preferably; 2. medicine of the present invention can make the antimony potassium tartrate induced mice turn round on average that the body number of times obviously reduces, incubation period significant prolongation and the pain threshold of hot plate experiment mice improve, its analgesia intensity is suitable with TONGSAIMAI PIAN 0.7g/kg; 3. the abdominal cavity capillary permeability that medicine of the present invention can obviously suppress due to the acetic acid increases.2.4 inside and outside bacteriostatic test:
1. adopt the agar doubling dilution to measure the outer antibacterial activity of stopping of medicine of the present invention to clinical isolating 105 strain Gram-positives and gram negative bacteria.The result shows: clinical common gram positive bacteria is had kills or bacteriostasis, and to the gram negative bacilli antibacterial activity a little less than; 2. select staphylococcus aureus, colon bacillus, Pseudomonas aeruginosa and four kinds of clinical common gram positive bacterias of enterococcus faecalis and gram negative bacteria; do the protection test of bacterial infection in the mice body; the result shows: medicine of the present invention has certain endogenous protective effect to staphylococcus aureus, enterococcus faecalis, a little less than the endogenous protective effect to colon bacillus, Pseudomonas aeruginosa.2.5 the measurement result to the immune function of mice test shows;
1. medicine of the present invention can significantly improve the phagocytic rate of normal mouse, and can resist weakening of the caused immunologic hypofunction mice of CY phagocytic function, makes it restore to normal; 2. medicine of the present invention has tangible synergy to the generation of normal mouse or the caused immunologic hypofunction mice of CY hemolysin; 3. medicine of the present invention has tangible synergy to the normal mouse splenocyte conversion capability that ConA stimulates, and also can resist the reduction of the caused immunologic hypofunction mouse spleen lymphocyte of CY conversion capability.
Because the comprehensive drug effect performance that medicine of the present invention is above is so established its clinical pharmacodynamics basis that is used for the treatment of peripheral vascular disease.3. acute toxicity test
Experimental session, none death of each treated animal.The all no abnormal discovery of mice outward appearance, mobility, response situation, the drinking-water of ingesting, feces and color.Hair color gloss, eye, the no abnormal secretions in oral cavity.Body weight gain and food ration Non Apparent Abnormality.Conclusion: medicine mice ig maximum dosage-feeding of the present invention is 140.72g/kg.4. long term toxicity test
This experimental observation 26 weeks of medicine continuous use of the present invention, the reaction of the long term toxicity of rat.Get 160 of health rats in 5 age in week, ♀ ♂ half and half is divided into matched group, low dose group, middle dosage group, high dose group at random.Every treated animal gastric infusion, 6 days weekly, continuous 26 weeks.Administration finishes the back and continues to observe for 4 weeks.Every day, the general behavior of observation experiment animal showed, the appetite body weight of record animal.Blood drawing detects the hematology when medication 7,13,26 week and 30 weeks, blood biochemical is learned index, and in medication during 13 weeks every group put to death 10 animals at random, when 26 weeks, put to death 20 animals at random for every group, put to death the residue animal during 30 weeks.Animal is cutd open inspection, and taking internal organ is weighed and is carried out histopathological examination.Experimental result is as follows:
1. continuous 26 weeks of gastric infusion of medicine 4.4g/kg of the present invention, animal general behavior, body weight gain, appetite, hematology, blood biochemical are learned, histopathologic examination does not see and the relevant toxic reaction of medicine medication of the present invention, except that part animal lungs occur being dispersed in the interstitial inflammation of distribution, every index is all no abnormal.
2. continuous 26 weeks of gastric infusion of medicine 8.8g/kg of the present invention, animal general behavior, body weight gain, appetite, hematology, blood biochemical are learned, histopathologic examination does not see and the relevant toxic reaction of medicine medication of the present invention, except that part animal lungs occur being dispersed in the interstitial inflammation of distribution, every index is all no abnormal.
3. medicine 17.6g/kg group of the present invention, continuously 26 weeks of gastric infusion, hematology, blood biochemical are learned the equal Non Apparent Abnormality of every index.Wherein male rat 10 to 26 all appetite/100 gram body weight are respectively organized lowly than other, and average weights alleviate after 21 weeks, the laboratory animal agitation, irritate the stomach difficulty, during 4 animal deads are arranged.Jenny general behavior, body weight gain, appetite Non Apparent Abnormality.Histopathologic examination: in 13 whens week, part animal lungs occur being dispersed in outside the interstitial inflammation of distribution, the cell infiltration of the special mess shape that being dispersed in appears in 4/10 animal livers, and hepatocyte does not see changes such as tangible cellular edema, steatosis.Do not see the obviously unusual of hepatic and renal tissue cell during 26 weeks, the interstitial inflammation of distribution appears being dispersed in part animal lungs.4 animal deads during this time, an animal dies from pneumorrhagia, an animal dies from myocardium hemorrhage, an animal dies of pneumonia, and an animal dies from myocarditis, convalescent period animal appetite, weight increase, hematology, blood biochemical are learned Non Apparent Abnormality, histopathologic examination is except that Non Apparent Abnormality appears being dispersed in the interstitial inflammation of distribution in minority animal lungs.Point out have certain toxicity 26 weeks of medicine 17.6g/kg continuous use of the present invention, should pay attention to during clinical practice.5. clinical research
From year March in June, 1997 to 1999, with medicine of the present invention 32 routine occlusive atherosclerotics are treated, carry out color Doppler ultrasonography and have 51 tremulous pulsies pathological changes is arranged.Male's 23 examples, women's 9 examples, at 42～79 years old age, the course of disease 3 months～9 years was treated 62～163 days.12 tremulous pulsies of first phase patient 7 examples, 19 tremulous pulsies of the second stage of patient's 13 examples, 16 tremulous pulsies of three phases, 1 grade of patient, 10 examples, 4 tremulous pulsies of three phases, 2 grades of patients, 2 examples.
Usage: each 4～6 of medicine of the present invention, every day 3 times, 1 month was 1 course of treatment, evaluated according to the diagnosis criterion of therapeutical effect that CAIM (Chinese Association Of Integrative Medicine) peripheral vascular disease Professional Committee formulates nineteen ninety-five.Clinical cure 10 examples (32.25%) among the 32 routine patients, 17 examples that significantly take a turn for the better (53.13%), progressive 3 examples (9.37%), total effective rate is 93.75%; 2 examples are implemented amputation, the equal first phase healing of the edge of a knife.Have the narrowness of 28 tremulous pulsies to reduce after the treatment, the blood flow velocity major part increases again.
In therapeutic process, anaphylaxis does not take place, liver function, renal function and three big routines are all no abnormal.
Therefore, medicine of the present invention has easy to use, and curative effect is reliable, the advantage that has no side effect.
(4) specific embodiment 1. embodiment 1
Take by weighing Radix Astragali 240g, Pheretima 400g, Eupolyphaga Seu Steleophaga 260g after the mixing, adds the water of ten times of amounts, decocts 2 hours, filters, and decocts once by same technology again, merges filtrate twice.Concentrating under reduced pressure is 1.30-1.35 to proportion, gets herbal decoction.
Take by weighing Scolopendra 150g, Scorpio 50g, oven dry is pulverized, and crosses the 80-90 mesh sieve, gets fine powder.
Herbal decoction and fine powder are mixed,, pulverize, cross 60 mesh sieves, obtain the 380g medicine after the sterilization, incapsulate, get product by each capsule 0.5g 60-65 ℃ of drying.
This medicine is by each 4～6, and every day 3 times, 1 month was 1 course of treatment, took.2. embodiment 2
Take by weighing Radix Astragali 400g, Pheretima 260g, Eupolyphaga Seu Steleophaga 400g, Scolopendra 50g, Scorpio 150g by the method for example 1 and the production worker technology of ordinary pill, can make pill.3. embodiment 3
Take by weighing Radix Astragali 320g, Pheretima 360g, Eupolyphaga Seu Steleophaga 320g, Scolopendra 120g, Scorpio 110g, the method by example 1 can be made into capsule.4. embodiment 4
Take by weighing Radix Astragali 450g, Pheretima 260g, Eupolyphaga Seu Steleophaga 400g after the mixing, adds the water of ten times of amounts, decocts 2 hours, filters, and decocts once by same technology again, merges filtrate twice.Concentrating under reduced pressure is 1.30-1.35 to proportion, gets herbal decoction.
Take by weighing Radix Salviae Miltiorrhizae 100g, Radix Angelicae Sinensis 150g, Radix Cyathulae 300g, 75% the ethanol that adds 8 times of amounts, reflux, extract, 2 hours, using the same method refluxes again respectively extracts 1.5 hours twice, merge three times extracting solution, concentrating under reduced pressure extracting solution to proportion is 1.30-1.35, gets the pure cream of getting.
Take by weighing Scolopendra 90g, Scorpio 110g, oven dry is pulverized, and crosses the 80-90 mesh sieve, gets fine powder.
With herbal decoction, alcohol extraction cream and fine powder mix, and 60-65 ℃ of drying, pulverize, and cross 60 mesh sieves.Obtain the 460g medicine after the sterilization, incapsulate, get product by each capsule 0.8g.
This medicine is by each 4～6, and every day 3 times, 1 month was 1 course of treatment, took.5. embodiment 5
Take by weighing Radix Astragali 240g respectively, Pheretima 300g, Eupolyphaga Seu Steleophaga 380g, Radix Salviae Miltiorrhizae 120g, Radix Angelicae Sinensis 180g, Radix Cyathulae 150g, Scolopendra 60g, Scorpio 130g by the technology of example 4 and the production technology of ordinary glazes tablet, can make sugar coated tablet.6. embodiment 6
Take by weighing Radix Astragali 380g respectively, Pheretima 260g, Eupolyphaga Seu Steleophaga 250g, Radix Salviae Miltiorrhizae 240g, Radix Angelicae Sinensis 120g, Radix Cyathulae 180g, Scolopendra 150g, Scorpio 50g by the technology of example 4 and the production technology of ordinary pill, makes pill.7. embodiment 7
Take by weighing Radix Astragali 380g respectively, Pheretima 360g, Eupolyphaga Seu Steleophaga 320g, Radix Salviae Miltiorrhizae 170g, Radix Angelicae Sinensis 170g, Radix Cyathulae 170g, Scolopendra 120g, Scorpio 120g, the technology by example 4 makes capsule.
Claims (7)
1. a medicine for the treatment of the peripheral vessels thrombotic disease is characterized in that it being the medicament of being made by the following weight proportion raw material
Radix Astragali 200-400 Pheretima 200-400 Eupolyphaga Seu Steleophaga 200-400
Scolopendra 50-150 Scorpio 50-150
2. the medicine of treatment peripheral vessels thrombotic disease according to claim 1, wherein the weight proportion of each raw material is
Radix Astragali 300-400 Pheretima 300-400 Eupolyphaga Seu Steleophaga 300-400
Scolopendra 80-120 Scorpio 80-120
3. the medicine of the described treatment peripheral vessels of claim 1 thrombotic disease is characterized in that: be the medicament of being made by the following weight proportion raw material
Radix Astragali 200-400 Pheretima 200-400 Eupolyphaga Seu Steleophaga 200-400
Scolopendra 50-150 Scorpio 50-150
Radix Salviae Miltiorrhizae 100-300 Radix Angelicae Sinensis 100-300 Radix Cyathulae 100-300
4. the medicine of treatment peripheral vessels thrombotic disease according to claim 3, wherein the weight proportion of each raw material is
Radix Astragali 300-400 Pheretima 300-400 Eupolyphaga Seu Steleophaga 300-400
Scolopendra 80-120 Scorpio 80-120
Radix Salviae Miltiorrhizae 120-240 Radix Angelicae Sinensis 120-240 Radix Cyathulae 120-240
5. the medicine of treatment peripheral vessels thrombotic disease according to claim 3, wherein the weight proportion of each raw material is
Radix Astragali 320-380 Pheretima 320-360 Eupolyphaga Seu Steleophaga 320-370
Scolopendra 90-120 Scorpio 90-120
Radix Salviae Miltiorrhizae 150-200 Radix Angelicae Sinensis 150-200 Radix Cyathulae 150-200
6. the medicine of treatment peripheral vessels thrombotic disease according to claim 3, wherein the weight proportion of each raw material is
The Radix Astragali 380 Pheretimas 360 Eupolyphaga Seu Steleophagas 320
Scolopendra 120 Scorpios 120
Radix Salviae Miltiorrhizae 170 Radix Angelicae Sinensis 170 Radix Cyathulaes 170
7. the medicine of treatment peripheral vessels thrombotic disease according to claim 1 and 2 is characterized in that: can make capsule, pill or other form of Chinese drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021515077A CN1301724C (en) | 2002-12-26 | 2002-12-26 | Medicine for thrombotic diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021515077A CN1301724C (en) | 2002-12-26 | 2002-12-26 | Medicine for thrombotic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1424083A true CN1424083A (en) | 2003-06-18 |
| CN1301724C CN1301724C (en) | 2007-02-28 |
Family
ID=4751992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021515077A Expired - Fee Related CN1301724C (en) | 2002-12-26 | 2002-12-26 | Medicine for thrombotic diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1301724C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019011289A (en) * | 2017-06-30 | 2019-01-24 | 小林製薬株式会社 | Tablet including cinnamomi cortex |
-
2002
- 2002-12-26 CN CNB021515077A patent/CN1301724C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019011289A (en) * | 2017-06-30 | 2019-01-24 | 小林製薬株式会社 | Tablet including cinnamomi cortex |
| CN110769859A (en) * | 2017-06-30 | 2020-02-07 | 小林制药株式会社 | Tablet containing Achyranthis radix processed product |
| JP7158831B2 (en) | 2017-06-30 | 2022-10-24 | 小林製薬株式会社 | Tablet containing goshitsu processed material |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1301724C (en) | 2007-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007009291A1 (en) | A pharmaceutical composition of traditional chineses medicine for treating rheumatoid arthritis and preparation thereof | |
| CN112791160A (en) | Uric acid-reducing anti-inflammatory analgesic medicinal and edible traditional Chinese medicine composition and preparation method thereof | |
| CN1069542C (en) | Medicine for treating chronic hepatism and its preparing process | |
| CN1301724C (en) | Medicine for thrombotic diseases | |
| CN102133273A (en) | Traditional Chinese medicine lipid-lowing and aperient capsule and preparation method thereof | |
| CN1272027C (en) | Desmodium preparation for treating urinary calculus, infection and cholelithiasis cholecy stolithiasis and chole cystitis and its production method | |
| CN115581730A (en) | Traditional Chinese medicine composition for preventing and treating deep venous thrombosis and application thereof | |
| CN1879783A (en) | A medicine for treating diabetes | |
| CN101987188B (en) | Biological Chinese patent medicine for preventing and treating hyperlipidemia | |
| CN101028482A (en) | Stomach-clearing pill | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN109758505B (en) | Traditional Chinese medicine composition for treating gouty arthritis and preparation method and application thereof | |
| CN115154535B (en) | Traditional Chinese medicine compound for improving atherosclerosis and preparation method thereof | |
| CN116999533B (en) | Heart-nourishing and pulse-activating granule, preparation method thereof and application thereof in antidepressant product | |
| CN100339093C (en) | Compound medicine for treating coronary heart disease and angina pectoris and its preparing process | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
| CN1053381C (en) | Drug for promoting puerperal physiological recovery and curing postpartum disease | |
| CN1279965C (en) | Traditional Chinese medicine preparation for treating cranial vascular diseases, its preparation method and application | |
| CN100342902C (en) | Anti-cancer drug and process for preparing the same | |
| CN1242772C (en) | Chinese medicine for hemorrhoid | |
| CN105596893A (en) | Traditional Chinese medicine composition for treating hyperlipidaemia and preparation method | |
| CN1169543C (en) | Fat reducing health care product and its preparing method | |
| CN116617290A (en) | Traditional Chinese medicine composition for treating diabetic foot disease | |
| CN1183297A (en) | Katsutoxin pill for tumor and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CI01 | Publication of corrected invention patent application |
Correction item: Patentee Correct: STAR PHARMACEUTICAL Ltd. False: Hainan Star Pharmaceutical Co.,Ltd. Number: 09 Page: 983 Volume: 23 |
|
| CI03 | Correction of invention patent |
Correction item: Patentee Correct: STAR PHARMACEUTICAL Ltd. False: Hainan Star Pharmaceutical Co.,Ltd. Number: 09 Page: The title page Volume: 23 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070228 Termination date: 20211226 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |